Literature DB >> 7533495

Discoordinate gene expression of aggrecan and type II collagen in experimental osteoarthritis.

J R Matyas1, M E Adams, D Huang, L J Sandell.   

Abstract

OBJECTIVE: To quantify the gene expression of aggrecan core protein and type II collagen in an experimental animal model of osteoarthritis (OA).
METHODS: Total RNA was extracted from the articular cartilage of unoperated knee joints and from OA joints produced by anterior cruciate ligament transection. The relative amounts of type II collagen and aggrecan core protein messenger RNA (mRNA) were evaluated by Northern blot analysis.
RESULTS: Total RNA was elevated 2.5 times, aggrecan mRNA was elevated 2 times, and type II collagen mRNA was elevated 8 times, in OA knees compared to unoperated controls.
CONCLUSION: Chondrocytes are activated metabolically in response to joint injury. Discoordinate gene expression of aggrecan and type II collagen is characteristic of early experimental OA, and we speculate that it may contribute to its pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533495     DOI: 10.1002/art.1780380320

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  22 in total

1.  An evaluation of the delayed effect of intra-articular injections of lidocaine (2%) on articular cartilage: an experimental study in rabbits.

Authors:  Hamidreza Yazdi; Bahahreh Tabatabaeian Nimavard; Mohammadali Shokrgozar; Mohammadmehdi Dehghan; Reza Jamei Moayedi; Mohammad Majidi; Tahmineh Mokhtari
Journal:  Eur J Orthop Surg Traumatol       Date:  2014-12

2.  Phenotypic modulation of chondrocytes as a potential therapeutic target in osteoarthritis: a hypothesis.

Authors:  T Aigner; J Dudhia
Journal:  Ann Rheum Dis       Date:  1997-05       Impact factor: 19.103

Review 3.  Chondropenia: current concept review.

Authors:  A Speziali; M Delcogliano; M Tei; G Placella; M Chillemi; R Tiribuzi; G Cerulli
Journal:  Musculoskelet Surg       Date:  2015-06-13

4.  Mild degenerative changes of hip cartilage in elderly patients: an available sample representative of early osteoarthritis.

Authors:  Bo Wei; Qiangrong Gu; Dong Li; Junwei Yan; Yang Guo; Fengyong Mao; Yan Xu; Fengchao Zang; Liming Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

5.  Expression of early and late differentiation markers (proliferating cell nuclear antigen, syndecan-3, annexin VI, and alkaline phosphatase) by human osteoarthritic chondrocytes.

Authors:  D Pfander; B Swoboda; T Kirsch
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

6.  The effects of NSAIDs on types I, II, and III collagen metabolism in a rat osteoarthritis model.

Authors:  Yun-Sheng Ou; Chao Tan; Hong An; Dian-Ming Jiang; Zheng-Xue Quan; Ke Tang; Xiao-Ji Luo
Journal:  Rheumatol Int       Date:  2011-06-17       Impact factor: 2.631

7.  Correlating high-resolution magic angle spinning NMR spectroscopy and gene analysis in osteoarthritic cartilage.

Authors:  Lauren Tufts; Keerthi Shet Vishnudas; Eunice Fu; John Kurhanewicz; Michael Ries; Tamara Alliston; Xiaojuan Li
Journal:  NMR Biomed       Date:  2015-03-12       Impact factor: 4.044

8.  Detecting structural changes in early experimental osteoarthritis of tibial cartilage by microscopic magnetic resonance imaging and polarised light microscopy.

Authors:  H A Alhadlaq; Y Xia; J B Moody; J R Matyas
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

9.  Evidence for altered synthesis of type II collagen in patients with osteoarthritis.

Authors:  F Nelson; L Dahlberg; S Laverty; A Reiner; I Pidoux; M Ionescu; G L Fraser; E Brooks; M Tanzer; L C Rosenberg; P Dieppe; A Robin Poole
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

10.  Advanced osteoarthritis in humans is associated with altered collagen VI expression and upregulation of ER-stress markers Grp78 and bag-1.

Authors:  Ashleigh E Nugent; Danielle M Speicher; Ian Gradisar; Denise L McBurney; Anthony Baraga; Kathleen J Doane; Walter E Horton
Journal:  J Histochem Cytochem       Date:  2009-06-22       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.